CORRECTION article

Front. Oncol., 08 December 2022

Sec. Neuro-Oncology and Neurosurgical Oncology

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1100854

Corrigendum: Vestibular schwannoma associated with neurofibromatosis type 2: Clinical course following stereotactic radiosurgery

  • 1. Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

  • 2. Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Article metrics

View details

1

Citations

933

Views

558

Downloads

In the published article, there was a misprint in affiliations. Instead of “Department of Neurosurgery, Asan Medical Center, Seoul, South Korea” it should be “Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea”. Additionally, instead of “Department of Radiology, Asan Medical Center, Seoul, South Korea” it should be “Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

neurofibromatosis type 2 (NF2), vestibular schwannoma (acoustic neuroma), stereotactic radiosurgery (SRS), tumor control, hearing preservation

Citation

Kim J, Byeon Y, Song SW, Cho YH, Hong C-K, Hong SH, Kim JH, Lee DH, Park JE, Kim HS and Kim Y-H (2022) Corrigendum: Vestibular schwannoma associated with neurofibromatosis type 2: Clinical course following stereotactic radiosurgery. Front. Oncol. 12:1100854. doi: 10.3389/fonc.2022.1100854

Received

17 November 2022

Accepted

18 November 2022

Published

08 December 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

12 - 2022

Updates

Copyright

*Correspondence: Young-Hoon Kim,

This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Oncology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics